Pharma Marketletter - Sanofi-Aventis’ Acomplia provides long-term cardiovascular benefits; two-year study.
New findings reported at the American Heart Association Scientific Sessions in New Orleans, Louisiana, show that first-year improvements in cardiovascular risk factors seen in obese patients treated with Sanofi-Aventis’ Acomplia (rimonabant) are sustained in the second year of therapy.
Related Results
Cheyenne, Wyo.-area doctors skeptical of ’super bill’ for weight loss, smoking.
Pounds-off prescription
Blockbuster obesity drug aims to win $4bn sales for Sanofi-Aventis
Obesity drug ‘to make a splash’.(Sanofi-Aventis)
Long-Term Benefits of Rimonabant Confirmed in Two-Year Study.
RIO (Rimonabant In Obesity)-North America was a Phase III, multicenter, randomized, double-blind, placebo-controlled trial which compared two fixed-dose regimens of Acomplia (5mg and 20mg once-daily) to placebo for a period of two years. The study involved …
Want to read the whole article? You can purchase it here. It’s quick and easy.
